Disable ads (and more) with a premium pass for a one time $4.99 payment
Monitoring for necrotizing enterocolitis (NEC) is essential for a newborn whose mother received indomethacin (Indocin) during preterm labor. Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) commonly used to relax the uterus and prolong pregnancy. However, it can have significant effects on the fetus, particularly regarding gastrointestinal function.
NEC is a serious condition primarily seen in premature infants, characterized by inflammation and possible necrosis of the intestines. Infants exposed to maternal NSAID use in the third trimester may be at an increased risk for this condition, as NSAIDs can affect blood flow to the intestines and disrupt normal gastrointestinal maturation.
Considering the context, while other conditions like duodenal atresia, Hirschsprung disease, and congenital heart defects can occur in neonates, they are less directly associated with the maternal use of indomethacin. The awareness of NEC after indomethacin treatment is crucial for prompt identification and management, which can significantly impact outcomes for the preterm infant. Therefore, observing for symptoms of NEC, such as feeding intolerance, abdominal distension, and changes in vital signs, becomes a priority in the care of the newborn.